Read as PDF
Lund, Sweden, 9th of May 2017 – The Board of Xintela AB (publ) announces that Keld Søndergaard has been nominated for election as a new member of the Board at the annual general meeting on the 18th of May 2017. Also proposed for re-election are Greg Batcheller, Karin Wingstrand, Sven Kili and Claes Post. The proposal is supported by shareholders who represent a majority of the company´s outstanding shares and votes. It is also announced that board member Anders Ermén has decided not to stand for re-election.
Keld Søndergaard has more than 30 years of experience from leadership positions in companies within the industrial sector, asset management and biotech. He is currently the CFO of Dermtreat ApS, a company developing an innovative drug delivery system. He has also co-founded and developed Accunia to become a successful asset management company with more than DKK 5,7 billion in assets under management.
“Electing Keld Søndergaard as a member of the Board would broaden Xintela´s expertise within developing and financing companies during periods of strong growth. His knowledge, experience and network of contacts are of great value to the company as our ambition is to maintain a high pace in our ongoing development projects within regenerative medicine and cancer while aiming to initiate clinical studies”, says Xintela's Chairman of the Board Gregory Batcheller.
The Board would also like to thank Anders Ermén for his active involvement as a member of the Board since 2013 and wishes him every success with his ongoing and future assignments.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Medicon Village 223 81 Lund
For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
About Xintela Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces. The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
This information is information that Xintela AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the contact persons set out above on 9 May 2017, at 08:45 CET.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO